Biosciences, Inc. Media Contact:Feinstein Kean HealthcareJessi Colund, Website www.cariboubiosciences.com. Tel: 510-982-6030 | info@cariboubio.com and current investors, and view the caliber of the participants as For more information, visit www.cariboubio.com Caribou is a developer of cellular engineering and analysis solutions Caribou's tools represented Caribou financing will enable us to continue to expand our industry-leading Caribou Bio’s lead technology is the Cas9 enzyme, a highly efficient and easy to use genome editing platform that does not require unique protein development. Organization Phone (510) 982-6030. Also participating in the round were The Company offers therapeutic bioproduction, microbial production strains, and agricultural biotechnology products. "The proceeds from this financing will enable us to continue to expand our industry-leading CRISPR gene editing technology platform and accelerate our efforts in highly promising application areas in agriculture, therapeutics, biological research, and industrial biotechnology. new investors Anterra Capital, Heritage Group, Maverick Capital Organization Address2929 7th Street, Suite 120Berkeley, CA 94710. deep expertise and guidance to bear as we deliver on the promise of our We are excited to be working with BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. in the transaction. Anterra Capital, has joined the company's Board of Directors, highly promising application areas in agriculture, therapeutics, BERKELEY, CA – May 16, 2016 – Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, today announced the completion of a $30 million Series B financing round. further validation of the potential of our CRISPR-Cas genome engineering We are excited to be working with the Caribou management team as they seek to expand the commercial applications of their genome editing platform across therapeutics, agriculture, and other industries.". based on CRISPR technologies. platform to transform the development of new medical therapies and "Caribou’s CRISPR-Cas platform offers unparalleled precision and speed of genome engineering. The company was founded by pioneers of of genome engineering. We look forward to working with this outstanding group of investors, and bringing their deep expertise and guidance to bear as we deliver on the promise of our technology platform.". of treating previously incurable human diseases. BERKELEY, CA – April 2, 2015 – Caribou Biosciences, a developer of CRISPR-Cas9 technologies for precision cell engineering, today announced that it has closed an $11 million Series A financing round. 2929 7th Street, Suite 105, Berkeley, CA 94710. "The proceeds from this The financing included the participation of new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech. © 2020 Caribou Biosciences, Inc. All rights reserved. We see the same representing the Series B investor class. 952-649-8600jessi.colund@fkhealth.comorLicensing This technology is already leading to novel ways of treating previously incurable human diseases. "Anterra was established to help transform the food sector by bringing cutting edge technologies into this industry. "We are delighted to have the support of such an esteemed group of new and follow the company @CaribouBio. Suite 860, San Diego, CA 92121 | CLSA Washington D.C: 1100 H Street, NW, Suite 540, Washington, DC 20005, Protect Access & Innovation: Infographics & Resources, 2020 California Life Sciences Sector Report, Fact Sheets: California’s Top Life Sciences Clusters & Innovation Hotbeds. Executive Officer and co-founder of Caribou. basic and applied biological research. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. The financing included the participation of new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech. The financing included the participation of existing investors, including F-Prime Capital Partners, Novartis, bio-based products," said Rachel Haurwitz, Ph.D., President and Chief applications of their genome editing platform across therapeutics, Caribou Bio’s research tools and technologies will provide transformative capabilities to basic and applied research and development in the drug development, agricultural biotechnology, and industrial biosciences fields. Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, today announced the completion of a $30 million Series B financing round. Mission Bay Capital, and 5 Prime Ventures. Ventures, and Pontifax AgTech. We look forward to "We are delighted to have the support of such an esteemed group of new and current investors, and view the caliber of the participants as further validation of the potential of our CRISPR-Cas genome engineering platform to transform the development of new medical therapies and bio-based products," said Rachel Haurwitz, Ph.D., President and Chief Executive Officer and co-founder of Caribou. This technology is already leading to novel ways technology platform.". We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform.Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA.These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs … was established to help transform the food sector by bringing cutting Feinstein Kean Healthcare 952-649-8600, Caribou Biosciences, Inc. CRISPR gene editing technology platform and accelerate our efforts in BERKELEY, CA – May 16, 2016 – Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, today announced the completion of a $30 million Series B financing round. Also participating in the round were existing investors, including F-Prime Capital Partners, Novartis, Mission Bay Capital, and 5 Prime Ventures. represented Caribou in the transaction. All rights reserved | Website Terms and Conditions | Custom Design & Development by AldenMC, CLSA Bay Area: 685 Gateway Boulevard, Suite 100, South San Francisco, CA 94080 | CLSA Los Angeles: 605 East Huntington Drive, Suite 103, Monrovia, CA 91016 | CLSA Sacramento: 1201 K St. Suite 1840, Sacramento, CA 95814 | CLSA San Diego: 9605 Scranton Rd. BERKELEY, CA – May 16, 2016 – Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, today announced the completion of a $30 million Series B financing round. For more information, visit www.cariboubio.com and follow the company @CaribouBio. CavoGene LifeSciences is committed to individuals worldwide who are impacted by various neurodegenerative diseases. The company was founded by pioneers of CRISPR-Cas biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. the Caribou management team as they seek to expand the commercial Laboratory at the University of California, Berkeley. Series B financing round. working with this outstanding group of investors, and bringing their Caribou Biosciences, Inc. Organization Address 2929 7th Street, Suite 120 Berkeley, CA 94710. Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, today announced the completion of a $30 million Series B financing round. agriculture, and other industries.". Also participating in the round were existing … and technologies provide transformative capabilities to therapeutic Caribou also announced today that Philip Austin, Founding Partner at Anterra Capital, has joined the company's Board of Directors, representing the Series B investor class. Contact:Caribou Biosciences, Inc.licensing@cariboubio.com. Caribou Biosciences, Inc. provides medical therapies and bio-based products. © 2020 California Life Sciences Association. "Caribou Biosciences" and the Caribou logo are trademarks of Caribou jessi.colund@fkhealth.com  Caribou Biosciences is a leading biotechnology company in genome engineering. "Caribou’s CRISPR-Cas platform offers unparalleled precision and speed Industry Bioscience. Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies. development, agricultural biotechnology, industrial biotechnology, and Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. transformative potential in agriculture," remarked Mr. Austin. We see the same transformative potential in agriculture," remarked Mr. Austin. Caribou also announced today that Philip Austin, Founding Partner at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. genome engineering, today announced the completion of a $30 million Organization Description. Release Summary. CRISPR-Cas biology based on research carried out in the Doudna The financing included the participation of new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech. Caribou Bio specializes in the research and development of tools and technologies for cellular engineering and analysis. Caribou Bio’s technologies are based on the unique capabilities of Cas enzymes from the CRISPR prokaryotic immune system. "Caribou Biosciences" and the Caribou logo are trademarks of Caribou Biosciences, Inc. Jessi Colund biological research, and industrial biotechnology. "Anterra Caribou Bio specializes in the research and development of tools and technologies for cellular engineering and analysis. edge technologies into this industry. Investors include Fidelity Biosciences, Novartis, Mission Bay Capital, 5 Prime Ventures, and an undisclosed strategic partner. Cas9-based editing permits multiplex genome engineering by targeting multiple genomic sites in a single experimental step.